Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

NCT07394062 · clinicaltrials.gov ↗

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Nonsmall Cell Lung Cancer, Stage IV
Metastatic Nonsmall Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Nivolumab
DRUG: Ipilimumab (1mg/kg)

Sponsor

Gazi University